Percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma.
This review was focused on a new intra-arterial infusion system with an extracorporeal chemofiltration circuit. After inferior vena cava isolation was percutaneously achieved by balloon catheter technique, cisplatin (140-240 mg/m(2)) was administered by intrauterine arterial infusion, with inferior and superior gluteal arterial embolization. The platinum-containing blood was pumped through an extracorporeal charcoal chemofiltration circuit. The percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) achieved a super high-dose cisplatin perfusion with the minimal adverse effects, allowing cisplatin dose escalation with further augmented tumor response. The results obtained in 23 patients who received neoadjuvant chemotherapy under PPPEC demonstrate that PPPEC has a better therapeutic advantage because of prompt tumor down-staging of locally advanced uterine cervical carcinoma with minimal adverse effects.
Maruo
Takeshi
T
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kusunoki-cho, 7-Chome, Chuo-ku, Kobe, Japan. maruo@kobe-u.ac.jp
Motoyama
Satoru
S
Hamana
Shinya
S
Yoshida
Shigeki
S
Ohara
Noriyuki
N
Yamasaki
Mineo
M
Ku
Yonson
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D002945:Cisplatin